A detailed history of Spire Wealth Management transactions in Cassava Sciences Inc stock. As of the latest transaction made, Spire Wealth Management holds 30 shares of SAVA stock, worth $76. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30
Holding current value
$76
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$9.57 - $35.08 $287 - $1,052
30 New
30 $0
Q4 2023

Feb 06, 2024

BUY
$12.64 - $30.11 $379 - $903
30 New
30 $0
Q1 2021

May 21, 2021

BUY
$7.09 - $87.95 $212 - $2,638
30 New
30 $1,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $102M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Spire Wealth Management Portfolio

Follow Spire Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Spire Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Spire Wealth Management with notifications on news.